Endocrinology, Vol 137, 5476-5483, Copyright © 1996 by Endocrine Society

ARTICLES

Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP

QF Wang, KI Tilly, JL Tilly, F Preffer, AL Schneyer, WF Crowley Jr and PM Sluss
Department of Medicine, National Cooperative Program for Infertility Research, Massachusetts General Hospital/Harvard Medical School, Boston 02114, USA.

LNCaP cells, derived from an androgen-sensitive cell line widely employed as an in vitro model of human prostate cancer, have been shown to express activin receptors. Activin is a local regulator of cellular growth, appears to play a key role in mesoderm induction and differentiation during development, and has been implicated in gonadal tumorigenesis. Follistatin, a monomeric glycoprotein that specifically binds and neutralizes activin, is often coexpressed with activin and, thus, modulates the autocrine/paracrine biological activity of this potent growth factor. We tested the hypothesis that LNCaP growth is modulated by the activin/follistatin system. Recombinant human activin A inhibited [3H]thymidine incorporation in a dose-dependent fashion with an ED50 of approximately 0.43 +/- 0.3 nM. Activin (0.1-3 nM) also inhibited dihydrotestosterone (DHT)-stimulated [3H]thymidine incorporation in LNCaP cells. Similarly, recombinant human inhibin A inhibited LNCaP proliferation, but was only 1/100th as potent as activin. Furthermore, activin (3 nM) induced a 3-fold increase in the extent of labeling of low mol wt DNA fragments typical of apoptosis. Activin-induced apoptosis was also indicated by an increase in the number of cells with reduced DNA content, as measured by flow cytometry of activin-treated cells. Both activin-mediated inhibition of cell proliferation and induction of apoptosis could be completely blocked by recombinant human follistatin. Based upon these results using an in vitro model, we speculate that activin functions locally to oppose androgen-driven cell proliferation and, thus, is a key factor controlling prostate growth. Reduced activin biosynthesis, increased follistatin secretion, or signaling defects in the activin receptor system should be further investigated in future studies as potential mechanisms underlying enhanced androgen-independent growth of human prostate cancer cells.

This article has been cited by other articles:

				N. C. Robson, D. J. Phillips, T. McAlpine, A. Shin, S. Svobodova, T. Toy, V. Pillay, N. Kirkpatrick, D. Zanker, K. Wilson, et al. Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production Blood, March 1, 2008; 111(5): 2733 - 2743. [Abstract] [Full Text] [PDF]

				Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683. [Abstract] [Full Text] [PDF]

				G. Chen, M. Nomura, H. Morinaga, E. Matsubara, T. Okabe, K. Goto, T. Yanase, H. Zheng, J. Lu, and H. Nawata Modulation of Androgen Receptor Transactivation by FoxH1: A NEWLY IDENTIFIED ANDROGEN RECEPTOR COREPRESSOR J. Biol. Chem., October 28, 2005; 280(43): 36355 - 36363. [Abstract] [Full Text] [PDF]

				K.-Y. Kim, K.-C. Choi, S.-H. Park, C.-S. Chou, N. Auersperg, and P. C. K. Leung Type II Gonadotropin-Releasing Hormone Stimulates p38 Mitogen-Activated Protein Kinase and Apoptosis in Ovarian Cancer Cells J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3020 - 3026. [Abstract] [Full Text] [PDF]

				Y. Fujii, S. Kawakami, Y. Okada, Y. Kageyama, and K. Kihara Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E927 - E931. [Abstract] [Full Text] [PDF]

				J. L. Carey, L. M. Sasur, H. Kawakubo, V. Gupta, B. Christian, P. M. Bailey, and S. Maheswaran Mutually Antagonistic Effects of Androgen and Activin in the Regulation of Prostate Cancer Cell Growth Mol. Endocrinol., March 1, 2004; 18(3): 696 - 707. [Abstract] [Full Text] [PDF]

				C. Tessier, A. Prigent-Tessier, L. Bao, C. M. Telleria, S. Ferguson-Gottschall, G. B. Gibori, Y. Gu, J. M. Bowen-Shauver, N. D. Horseman, and G. Gibori Decidual Activin: Its Role In the Apoptotic Process and Its Regulation by Prolactin Biol Reprod, May 1, 2003; 68(5): 1687 - 1694. [Abstract] [Full Text] [PDF]

				E. Wiater and W. Vale Inhibin Is an Antagonist of Bone Morphogenetic Protein Signaling J. Biol. Chem., February 28, 2003; 278(10): 7934 - 7941. [Abstract] [Full Text] [PDF]

				D. C. Danila, X. Zhang, Y. Zhou, J. N. S. Haidar, and A. Klibanski Overexpression of Wild-Type Activin Receptor Alk4-1 Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4741 - 4746. [Abstract] [Full Text] [PDF]

				D. J. Bernard, S. C. Chapman, and T. K. Woodruff Minireview: Inhibin Binding Protein (InhBP/p120), Betaglycan, and the Continuing Search for the Inhibin Receptor Mol. Endocrinol., February 1, 2002; 16(2): 207 - 212. [Abstract] [Full Text] [PDF]

				Y.-G. Chen, H. M. Lui, S.-L. Lin, J. M. Lee, and S.-Y. Ying Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin Experimental Biology and Medicine, February 1, 2002; 227(2): 75 - 87. [Abstract] [Full Text] [PDF]

				L. You and F. E. Kruse Differential Effect of Activin A and BMP-7 on Myofibroblast Differentiation and the Role of the Smad Signaling Pathway Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 72 - 81. [Abstract] [Full Text] [PDF]

				D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo PNAS, January 1, 2002; (2002) 221599298. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				G. H. Su, R. Bansal, K. M. Murphy, E. Montgomery, C. J. Yeo, R. H. Hruban, and S. E. Kern ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma PNAS, March 13, 2001; 98(6): 3254 - 3257. [Abstract] [Full Text] [PDF]

				S. L. Mellor, M. Cranfield, R. Ries, J. Pedersen, B. Cancilla, D. de Kretser, N. P. Groome, A. J. Mason, and G. P. Risbridger Localization of Activin {beta}A-, {beta}B-, and {beta}C-Subunits in Human Prostate and Evidence for Formation of New Activin Heterodimers of {beta}C-Subunit J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4851 - 4858. [Abstract] [Full Text]

				D. C. Danila, W. J. Inder, X. Zhang, J. M. Alexander, B. Swearingen, E. T. Hedley-Whyte, and A. Klibanski Activin Effects on Neoplastic Proliferation of Human Pituitary Tumors J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1009 - 1015. [Abstract] [Full Text]

				S. K. Kang, K.-C. Choi, K. W. Cheng, P. S. Nathwani, N. Auersperg, and P. C. K. Leung Role of Gonadotropin-Releasing Hormone as an Autocrine Growth Factor in Human Ovarian Surface Epithelium Endocrinology, January 1, 2000; 141(1): 72 - 80. [Abstract] [Full Text] [PDF]

				S. J. McPherson, S. L. Mellor, H. Wang, L. W. Evans, N. P. Groome, and G. P. Risbridger Expression of Activin A and Follistatin Core Proteins by Human Prostate Tumor Cell Lines Endocrinology, November 1, 1999; 140(11): 5303 - 5309. [Abstract] [Full Text]

				M. Bruyninx, B. Hennuy, A. Cornet, P. Houssa, M. Daukandt, E. Reiter, J. Poncin, J. Closset, and G. Hennen A Novel Gene Overexpressed in the Prostate of Castrated Rats: Hormonal Regulation, Relationship to Apoptosis and to Acquired Prostatic Cell Androgen Independence Endocrinology, October 1, 1999; 140(10): 4789 - 4799. [Abstract] [Full Text]

				R. G. Pestell, C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal Regulation of Proliferation and Differentiation Endocr. Rev., August 1, 1999; 20(4): 501 - 534. [Abstract] [Full Text] [PDF]

				N. Di Simone, H. A. Hall, C. Welt, and A. L. Schneyer Activin Regulates {beta}A-Subunit and Activin Receptor Messenger Ribonucleic Acid and Cellular Proliferation in Activin-Responsive Testicular Tumor Cells Endocrinology, March 1, 1998; 139(3): 1147 - 1155. [Abstract] [Full Text] [PDF]

				T. Z. Thomas, H. Wang, P. Niclasen, M. K. O'Bryan, L. W. Evans, N. P. Groome, J. Pedersen, and G. P. Risbridger Expression and Localization of Activin Subunits and Follistatins in Tissues from Men with High Grade Prostate Cancer J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3851 - 3858. [Abstract] [Full Text] [PDF]

				J. W. M. Martens, J. P. de Winter, M. A. Timmerman, A. McLuskey, R. H. N. van Schaik, A. P. N. Themmen, and F. H. de Jong Inhibin Interferes with Activin Signaling at the Level of the Activin Receptor Complex in Chinese Hamster Ovary Cells Endocrinology, July 1, 1997; 138(7): 2928 - 2936. [Abstract] [Full Text] [PDF]

				D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo PNAS, January 8, 2002; 99(1): 239 - 244. [Abstract] [Full Text] [PDF]